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Allergic contact dermatitis (ACD) is a T cell–
mediated inflammatory skin disease most fre­
quently  caused  by  low  molecular  weight 
electrophilic chemicals or metal ions. Activation 
of DCs by contact allergens is a prerequisite for 
the  induction  of  the  pathogenic  skin­specific   
T  cell  response  (Martin  and  Jakob,  2008;   
Sigmundsdottir and Butcher, 2008).
DC activation proceeds via a broad variety   
of germline­encoded innate immune receptors, 
in particular the pattern recognition receptors, 
Toll­like receptors (TLRs) and NOD­like recep­
tors (NLRs; Kawai and Akira, 2009; Martinon   
et al., 2009; Palm and Medzhitov, 2009). TLR   
and  NLR  recognize  pathogen­associated  mo­
lecular patterns as well as endogenous danger 
signals (Tsan and Gao, 2004; Jiang et al., 2006; 
Palm and Medzhitov, 2009) associated with   
tissue destruction, termed damage­associated 
molecular patterns (Seong and Matzinger, 2004). 
Triggering of pattern recognition receptors   
by pathogen­associated molecular patterns or   
damage­associated molecular patterns leads to an 
inflammatory response involving the production 
of proinflammatory cytokines, including IL­1, 
chemokines, and antimicrobial peptides.
Inflammatory responses induced by contact 
allergens in the skin share many features with 
the  innate  immune  responses  to  pathogens 
(Freudenberg et al., 2009). In the mouse con­
tact hypersensitivity (CHS) model, we have re­
cently demonstrated a critical role for TLR2 
and TLR4 in the DC­mediated sensitization 
process (Martin et al., 2008). Moreover, contact 
allergens trigger oxidative stress and antioxidant 
responses (Matsue et al., 2003; Kim et al., 2008; 
Natsch and Emter, 2008; Ade et al., 2009).   
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Sensitization to contact allergens requires activation of the innate immune system by 
endogenous danger signals. However, the mechanisms through which contact allergens 
activate innate signaling pathways are incompletely understood. In this study, we demon-
strate that mice lacking the adenosine triphosphate (ATP) receptor P2X7 are resistant to 
contact hypersensitivity (CHS). P2X7-deficient dendritic cells fail to induce sensitization to 
contact allergens and do not release IL-1 in response to lipopolysaccharide (LPS) and ATP. 
These defects are restored by pretreatment with LPS and alum in an NLRP3- and ASC-
dependent manner. Whereas pretreatment of wild-type mice with P2X7 antagonists, the 
ATP-degrading enzyme apyrase or IL-1 receptor antagonist, prevents CHS, IL-1 injection 
restores CHS in P2X7-deficient mice. Thus, P2X7 is a crucial receptor for extracellular ATP 
released in skin in response to contact allergens. The lack of P2X7 triggering prevents IL-1 
release, which is an essential step in the sensitization process. Interference with P2X7 
signaling may be a promising strategy for the prevention of allergic contact dermatitis.
© 2010 Weber et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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Thus, ATP is an important endogenous mediator in inflam­
mation. It was recently shown that P2X7 triggering on DCs by 
ATP derived from dying tumor cells is a prerequisite for IL­1–
dependent antitumor responses, and this response was dependent 
on the NLRP3 inflammasome and caspase­1 (Ghiringhelli et al., 
2009). Furthermore, P2X7 activation on DCs is important in 
DC­mediated airway inflammation (Idzko et al., 2007). A proin­
flammatory role for ATP in CHS was suggested by the finding 
that injection of nonhydrolyzable ATP­S into mice before their 
sensitization resulted in increased ear swelling responses   
(Granstein et al., 2005). Interestingly, contact allergens can trigger 
the release of ATP from keratinocytes and DCs, and it was shown 
that ATP release from keratinocytes stimulates Langerhans cells 
(Mizumoto et al., 2002). However, the mechanisms by which 
ATP triggers inflammatory responses in CHS were unknown.
In this study, we have investigated the putative role of the 
ATP receptor P2X7 in CHS in vivo, including its mode of 
action. Using mice lacking P2X7 or WT mice treated with 
the P2X7 antagonist KN­62 (Baraldi et al., 2004) or the ATP­
degrading enzyme apyrase, we demonstrate for the first time 
that P2X7 is essential for the induction of CHS by contact al­
lergens in mice. We observed ATP release in the skin upon 
2,4,6­trinitrochloro­1­benzene (TNCB) painting, indicating 
indirect contact allergen–dependent P2X7 triggering via in­
duction of ATP release in the skin. In addition, we show by 
cell transfer experiments that expression of P2X7 on DCs is 
crucial for the sensitization but not for the effector phase of 
CHS. The sensitization defect of P2X7
/ DCs can be by­
passed by treatment with the NLRP3 inflammasome activa­
tor alum (Eisenbarth et al., 2008, Franchi and Núñez, 2008; 
Kool et al., 2008; Li et al., 2008). However, alum did not   
restore  the  absent  sensitization  capacity  of  NLRP3/  
(Martinon et al., 2006) or ASC/ (Sutterwala et al., 2006) 
DCs, indicating a link between ATP­mediated P2X7 triggering 
and NLRP3 inflammasome activation in IL­1 release. The 
crucial role of this cytokine in CHS was suggested by the 
prevention of CHS after injection of mice with the IL­1 re­
ceptor (IL­1R) antagonist (IL­1Ra) anakinra, which is used 
in  the  treatment  of  inflammatory  diseases  such  as  gout   
(So et al., 2007; Gabay et al., 2010), or the impaired CHS in   
IL­1R/ mice. Most importantly, injection of IL­1 into 
P2X7
/ mice restored their CHS response. Thus, interfering 
with purinergic signaling via P2X7 may be a promising ap­
proach for the prevention of ACD.
RESULTS
Mice deficient for the purinergic receptor P2X7  
are resistant to CHS
To study the role of extracellular ATP in CHS, we tested C57BL/6 
WT and P2X7­deficient (P2X7
/) mice for their ear swelling 
reaction to epicutaneous sensitization with the contact allergen 
TNCB. Mice were treated on the abdominal skin followed by 
elicitation of CHS on day 5 by application of TNCB to the ear 
skin. The increase in ear thickness was measured 24 h after elicita­
tion. Although WT mice developed a normal ear­swelling re­
sponse, P2X7
/ mice did not develop TNCB­induced CHS 
They  also  activate  the  NLRP3  inflammasome  (Sutterwala   
et al., 2006; Watanabe et al., 2007), a cytosolic platform which 
activates caspase­1 for the processing of pro–IL­1 and pro–
IL­18 produced, e.g., by keratinocytes and DC in response to 
various stimuli, including TLR, NLR, and the purinergic re­
ceptor P2X7 (Ferrari et al., 2006; Di Virgilio, 2007; Martinon 
et al., 2009; Surprenant and North, 2009). These cytokines 
play a key role in the sensitization phase of CHS and are key 
mediators of Langerhans cell migration from the skin to the 
draining lymph nodes (Shornick et al., 1996; Antonopoulos   
et al., 2001, 2008; Cumberbatch et al., 2001).
The molecular mechanisms by which contact allergens 
activate these innate immune and stress pathways are largely 
unknown. Recent evidence suggests that endogenous ligands 
such as fragments of hyaluronic acid may trigger TLR2 and 
TLR4 in CHS (Martin et al., 2008; Freudenberg et al., 2009). 
Similarly, extracellular nucleotides such as ATP released by 
stressed or damaged cells are endogenous danger signals that 
can activate innate immune responses. There are two families 
of purinergic receptors (P2R), i.e., P2Y and P2X (North and 
Surprenant, 2000; Abbracchio et al., 2006; Burnstock, 2008). 
P2Y receptors are G protein–coupled receptors, and P2X re­
ceptors are ligand­gated ion channels. The transmembrane 
ATP receptor P2X7 has been implicated in the posttransla­
tional processing of pro–IL­1 and pro–IL­18 via activation 
of the NLRP3 inflammasome (Solle et al., 2001; Ferrari et al., 
2006; Di  Virgilio, 2007; Dinarello, 2009; Martinon et al., 2009; 
Surprenant and North, 2009). This receptor is expressed on 
mouse DCs. P2X7­deficient DCs are severely impaired in   
IL­1 release and stimulation of antigen­specific T cells   
(Mutini et al., 1999).
ATP is the main energy carrier in cells with a cytosolic 
concentration of 3–10 mM. Under homeostatic conditions, 
extracellular ATP levels are as low as 10 nM and are tightly 
regulated by ectonucleotidases such as CD39 and CD73, 
which dephosphorylate ATP to ADP, AMP, and adenosine 
(Ferrari et al., 2006; Di Virgilio, 2007; Surprenant and North, 
2009). Adenosine has immunoregulatory functions in CHS 
(Ring et al., 2009). However, under pathological conditions 
such as hypoxia, trauma, viral, and bacterial infection and in­
flammation, extracellular concentrations of ATP can be ele­
vated as the result of active processes or passive leakage from 
damaged or dying cells. The concomitant down­regulation of 
nucleotidases causes additional accumulation of extracellular 
nucleotides (Robson et al., 1997; Lazarowski et al., 2003).
ATP­mediated K+ efflux from cells is triggered by en­
gagement of P2X7 and is crucial for LPS­mediated IL­1  
release from human macrophages (Ferrari et al., 1997). More­
over, LPS­primed macrophages from P2X7
/ mice fail to 
secrete mature IL­1 because of their inability to process the 
immature pro form. This defect can be repaired by treatment 
with nigericin (Solle et al., 2001), a P2X7­independent acti­
vator of the NLRP3 inflammasome. The NLRP3 inflamma­
some  is  activated  in  response  to ATP  and  is  required  for 
posttranslational IL­ processing (Mariathasan et al., 2006; 
Dinarello, 2009).JEM VOL. 207, November 22, 2010 
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Thus, the role of the P2X7 receptor on 
DCs in the induction and/or elicitation 
of CHS was assessed. BM­derived DCs 
(BMDCs) of WT and P2X7
/ mice 
were modified with TNBS and subse­
quently injected i.c. (intracutaneously) 
into WT recipients as described previ­
ously (Martin et al., 2008). TNBS­ 
modified  WT  BMDCs  effectively 
sensitized WT recipients (Fig. 2 A).   
In contrast, TNBS­modified P2X7
/ 
BMDCs  failed  to  sensitize WT  mice 
under  identical  conditions.  Together 
with the finding that TNBS­modified 
WT BMDCs were able to readily sen­
sitize P2X7
/ recipients (Fig. 2 B), 
these data indicate that expression of 
P2X7 on DCs is essential during the sensitization phase but not 
during the effector phase of CHS.
Alum pretreatment restores the sensitization capacity  
of P2X7-deficient BMDCs
The failure of P2X7
/ BMDCs to induce sensitization may 
be caused by their failure to produce mature IL­1 via the 
NLRP3 inflammasome (Ferrari et al., 2006; Mariathasan   
et al., 2006; Di Virgilio, 2007; Surprenant and North, 2009). 
Therefore, we bypassed the need for P2X7 triggering with 
alum, a potent P2X7­independent activator of the NLRP3 
inflammasome (Eisenbarth et al., 2008, Franchi and Núñez, 
2008; Kool et al., 2008; Li et al., 2008). BMDCs were pre­
treated with alum before adoptive transfer. TNBS­modified 
(Fig. 1 A). Similar results were obtained for the contact allergen 
oxazolone (Fig. 1 B). In contrast, P2X7­deficient mice developed 
normal ear swelling in response to the irritant croton oil   
(Fig. 1 C). These results identify a crucial role for the ATP­gated 
cation channel P2X7 in CHS induced by contact allergens. The 
results from ear thickness measurements are supported by histol­
ogy of the ear skin. In contrast to P2X7
/ mice, the ear skin of 
WT mice treated with TNCB shows a significant swelling and a 
more pronounced inflammatory infiltrate (Fig. 1 D).
2,4,6-trinitrobenzene-1-sulfonic acid (TNBS)–modified DCs 
from P2X7
/ mice fail to sensitize WT recipients for CHS
DCs are the main interface between innate and adaptive immu­
nity in CHS (Martin and Jakob, 2008; Freudenberg et al., 2009). 
Figure 1.  P2X7
/ mice are resistant to 
allergic but not to irritant contact derma-
titis. (A) C57BL/6 WT or P2X7
/ mice were 
sensitized by application of 3% TNCB in ac-
etone or acetone alone (vehicle) on the 
shaved abdominal skin. Both ears were chal-
lenged on day 5 after sensitization with 1% 
TNCB. Ear thickness was measured at the time 
of challenge and 24 h later. (B) The experi-
ment was performed as described in A, except 
with 3% oxazolone in ethanol or ethanol 
(vehicle). Ear challenge was performed on day 6  
with 1% oxazolone in ethanol. (C) WT and 
P2X7
/ mice were treated with 1% croton oil 
in 4:1 acetone/olive oil or acetone/olive oil 
alone (vehicle) on the ear skin. The ear thick-
ness was measured before and 24 h after 
treatment. (A–C) Results represent the in-
crease in ear thickness in groups of five mice ± 
SD. One of two (C) or three (A and B) inde-
pendent experiments is shown (***, P < 0.001). 
(D) Ear skin from TNCB-sensitized P2X7
/ 
and WT mice was stained with H&E 24 h after 
challenge with vehicle or TNCB.2612 P2X7 receptor in contact hypersensitivity | Weber et al.
are  required  in  DCs  for  successful   
sensitization. To  analyze  the  role  of 
NLRP3 in P2X7­mediated IL­1 pro­
cessing, WT  or  NLRP3/  BMDCs 
were stimulated in vitro with LPS and 
alum or with LPS and ATP. Neither 
alum  nor ATP  stimulation  increased 
the LPS­induced IL­1 secretion from 
NLRP3/ BMDC mice in contrast to BMDCs from WT 
mice (Fig. 3 C). These data demonstrate that the P2X7
/­ 
dependent IL­1 release is mediated via the NLRP3 inflam­
masome  and  confirm  the  important  role  of  NLRP3  in 
alum­mediated IL­1 processing (Eisenbarth et al., 2008; Kool 
et al., 2008; Li et al., 2008). IL­6 release was triggered effi­
ciently in both WT and NLRP3/ BMDCs, showing that 
there is no general functional defect of NLRP3/ BMDCs 
(unpublished data).
P2X7
/ BMDCs fail to process and secrete mature IL-1
To further address the functional consequence of P2X7 de­
ficiency in DCs, WT and P2X7
/ BMDCs were analyzed for 
the production and secretion of pro– and mature IL­1 by West­
ern blotting (Fig. 4 A) and for secreted IL­1 by ELISA (Fig. 4 B) 
in response to LPS and ATP in vitro. This cytokine is essential   
for  the  sensitization  process  in  CHS  (Shornick  et  al.,  1996;   
Antonopoulos et al., 2001, 2008; Cumberbatch et al., 2001). Both 
WT and P2X7
/ BMDCs produced similar amounts of pro–
IL­1 in response to LPS (Fig. 4 A), but only WT BMDCs se­
creted  mature  IL­1  when  challenged  with  LPS  and ATP, 
whereas P2X7
/ BMDCs did not (Fig. 4 B). These data show 
that induction of IL­1 release by TNCB is crucially dependent 
on ATP­mediated triggering of P2X7. It is worth noting that in 
both WT and P2X7
/ BMDCs, ATP alone was able to effi­
ciently induce pro–IL­1 (Fig. 4 A). This points to a P2X7
/­
independent effect on pro–IL­1 production. When BMDCs 
from both mouse strains were treated with graded concentrations 
of alum alone in vitro, no IL­1 release was observed (Fig. 4 C). 
However, the addition of 1 µg/ml LPS resulted in a dose­ 
dependent IL­1 release from BMDCs of WT and P2X7
/ 
and alum­pretreated P2X7
/ BMDCs regained their sensi­
tizing potential upon transfer into both WT and P2X7
/ recipi­
ents (Fig. 2 C). Alum pretreatment of WT BMDCs did not 
significantly alter their sensitizing potential (Fig. 2 D). These 
data further support the assumption that P2X7 on DCs is man­
datory for efficient induction of CHS and acts via processing and 
release of inflammasome­dependent cytokines such as IL­1 
(Ferrari et al., 2006; Mariathasan et al., 2006; Di Virgilio, 2007; 
Martinon et al., 2009; Surprenant and North, 2009).
Alum pretreatment fails to restore the sensitization 
capacity of NLRP3- or ASC-deficient BMDCs
To analyze the role of the NLRP3 inflammasome in DCs and 
the mechanism of the P2X7 bypass with alum, WT mice were 
sensitized with NLRP3/ (Martinon et al., 2006) BMDCs 
in comparison with WT and P2X7
/ BMDCs with and 
without alum pretreatment (Fig. 3 A). No CHS was elicited 
by TNCB challenge in mice sensitized with unmodified con­
trol DCs or alum pretreated control DCs of all three mouse 
strains. Moreover, we demonstrate that the lack of NLRP3 in 
BMDCs modified with TNBS abrogates their sensitization 
capacity. This defect was not prevented by alum pretreatment, 
indicating that the alum bypass of P2X7 is mediated by the 
NLRP3 inflammasome. In addition, we used BMDCs from 
ASC/ mice (Sutterwala et al., 2006) for sensitization (Fig. 3 B). 
As shown for NLRP3/ BMDCs, TNBS­modified ASC/ 
BMDCs also failed to sensitize WT mice for CHS, a defect 
which again could not be bypassed by alum pretreatment. 
These data support the notion that the NLRP3 inflamma­
some is important in CHS (Sutterwala et al., 2006; Watanabe 
et al., 2007) and demonstrate that functional ASC and NLRP3 
Figure 2.  P2X7 deficiency abrogates  
the sensitization capacity of BMDCs  
and is restored by alum pretreatment.  
(A and B) WT (A) or P2X7
/ (B) mice were 
sensitized by i.c. injection of 3 × 105 unmodi-
fied or TNP-modified WT or P2X7
/ BMDCs 
into the shaved abdominal skin. Ear challenge 
was performed as in Fig. 1. (C and D) The  
experiment was performed as described  
in A and B, but the indicated BMDCs were 
prestimulated or not with alum for 2 h before 
adoptive transfer. WT (C) or P2X7
/ mice (D) 
were sensitized by i.c. injection of 3 × 105 
BMDCs. (A–D) The data represent the mean 
increase in ear thickness of groups of five 
mice ± SD. One representative of three inde-
pendent experiments is shown (***, P < 0.001).JEM VOL. 207, November 22, 2010 
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imaging (Edinger et al., 2003) revealed that TNCB rapidly 
triggers ATP release, as detected by ATP­dependent luciferin­
induced  bioluminescence  from  HEK293­pmeLUC  cells 
(Pellegatti et al., 2008) after painting of the ear skin of mice 
(Fig. 5). These data reveal that P2X7 is triggered by the en­
dogenous danger signal ATP that is released from cells in the 
skin after TNCB treatment.
P2X7 antagonists or removal of extracellular ATP prevents CHS
To further investigate the role of the P2X7 receptor in CHS 
in vivo, experiments with the P2X7 receptor antagonist   
KN­62 (Baraldi et al., 2004) were performed in WT mice. Re­
cipients were injected with KN­62 into the left ear pinna, 
followed by sensitization with TNCB on the same ear 4 h 
later. CHS was elicited on day 5 with TNCB on the right ear, 
and the increase in ear thickness was measured 24 h after elic­
itation. As depicted in Fig. 6 A, pretreatment with KN­62   
before TNCB sensitization led to abrogation of CHS in WT 
mice. This effect was dose and time dependent (Fig. S1). Sim­
ilar results were obtained with the purinergic receptor antag­
onist suramin (Fig. S2; Baraldi et al., 2004). These data again 
indicate an essential role for P2X7 receptor signaling in CHS. 
mice (Fig. 4 D). These results and the results shown in Fig. 3 show 
a link between LPS­induced pro–IL­1 production and ATP­ 
and P2X7­dependent IL­1 processing and release. An important 
finding is that ATP triggering of P2X7 can be replaced by alum 
treatment of the BMDCs, which results in LPS­induced IL­1 
production and release of processed IL­1 not only in WT but 
also in P2X7
/ BMDCs (Fig. 4, C and D). Importantly, the alum 
effect is no longer visible when BMDCs from NLRP3/ or 
ASC/ mice are used for sensitization in CHS (Fig. 3, A and B). 
Moreover, alum also fails to restore defective LPS­induced IL­1 
release in NLRP3/ BMDCs in vitro (Fig. 3 C). These data 
support the notion that defective IL­1 release of P2X7
/ DCs 
is responsible for their failure to sensitize mice for CHS. They also 
strongly suggest that contact allergen–induced ATP triggering of 
P2X7 leads to IL­1 processing via the NLRP3 inflammasome, 
as demonstrated in other systems (Ferrari et al., 2006; Mariathasan 
et al., 2006; Di  Virgilio, 2007; Idzko et al., 2007; Ghiringhelli et al., 
2009; Surprenant and North, 2009).
TNCB triggers ATP release in vivo in mouse skin
We next analyzed whether ATP is released in the skin after 
application of the contact allergen TNCB. Bioluminescence 
Figure 3.  NLRP3 or ASC deficiency abrogates the sensitization capacity of BMDCs and is not restored by alum pretreatment.  
(A and B) NLRP3/, P2X7
/, and WT BMDCs (A) or ASC/ and WT BMDCs (B) were TNBS modified and alum pretreated where indicated, and the experi-
ment was performed as described in Fig. 2. The data represent the mean increase in ear thickness of groups of five mice ± SD. One representative of three 
(NLRP3) and two (ASC) independent experiments is shown (**, P < 0.005; ***, P < 0.001). (C) NLRP3/ and WT BMDCs were treated with 0.1 µg/ml LPS, 
1.25 mM ATP, 80 µg/ml alum, or the indicated combination of two stimuli for 12 h. IL-1 secretion was determined by ELISA. Data represent the mean of 
triplicate measurements ± SD and are representative for two independent experiments (*, P < 0.05; **, P < 0.005; ***, P < 0.001).2614 P2X7 receptor in contact hypersensitivity | Weber et al.
These data underline the role of IL­1R 
signaling and the crucial pathogenic role 
of IL­1 for the sensitization to con­
tact  allergens  (Shornick  et  al.,  1996; 
Antonopoulos  et  al.,  2001,  2008; 
Cumberbatch et al., 2001).
DISCUSSION
The  mechanisms  by  which  contact   
allergens activate innate immune and 
stress responses in skin are only poorly 
understood. We have recently demon­
strated a crucial role for the innate immune receptors TLR2 
and TLR4 and the cytokine receptor IL­12R2 in the sensiti­
zation phase of CHS (Martin et al., 2008). These receptors are 
indirectly triggered by contact allergens via induction of en­
dogenous ligands such as fragments of the extracellular matrix 
component hyaluronic acid. So far, only Ni2+ has been identi­
fied as a contact allergen that directly triggers human TLR4 by 
binding to conserved histidine residues that are not present in 
mouse TLR4 (Schmidt et al., 2010). This explains why CHS to 
Ni2+ in mice requires coapplication of adjuvants.
Besides the TLRs, a role for the NLRP3 inflammasome in 
CHS has been demonstrated (Sutterwala et al., 2006; Watanabe 
et al., 2007). In the present study, we show that P2X7 signaling 
in DCs is a crucial step in the sensitization phase of CHS. Inter­
estingly, irritant contact dermatitis induced by croton oil is not 
affected in P2X7
/ mice. However, these mice are resistant to 
contact allergen–induced CHS. P2X7
/ DCs are incapable of 
sensitizing WT mice for CHS, whereas WT DCs efficiently 
sensitize P2X7
/ mice. The reconstitution of the sensitization 
capacity of P2X7
/ DCs by pretreatment with alum, a P2X7­
independent activator of the NLRP3 inflammasome (Eisenbarth 
et al., 2008, Franchi and Núñez, 2008; Kool et al., 2008; Li et al., 
2008), supports the functional role of the inflammasome in 
CHS  (Sutterwala  et  al.,  2006; Watanabe  et  al.,  2007)  and   
To assess the role of endogenously released ATP in CHS, WT 
mice were injected with apyrase, an ATP­degrading enzyme, 
to remove ATP from the extracellular space (Idzko et al., 2007) 
using the same approach as described for KN­62 (Fig. 6 A).   
Injection of apyrase into the ear pinna before sensitization pre­
vented CHS in WT mice (Fig. 6 B). A dose­ and time­dependent   
reduction of the ear swelling response was observed (Fig. S3). 
These results underline the crucial role for the release of   
extracellular ATP in the sensitization phase of CHS.
IL-1R blockade or deficiency abrogates CHS, whereas IL-1 
restores CHS in P2X7
/ mice
Finally, to assess the role of IL­1 in CHS, we neutralized the 
effects of this cytokine by i.v. injection of the recombinant 
IL­1Ra anakinra before sensitization of  WT mice with  TNCB. 
After ear challenge, we observed that anakinra treatment effi­
ciently prevented the CHS response (Fig. 7 A). When we 
tried to induce CHS in IL­1R/ mice, we observed a similar 
effect. In contrast to IL­18/ mice, CHS was significantly 
reduced (Fig. 7 B). Because IL­1R signaling is not confined 
to IL­1, we addressed the role of this cytokine by pretreat­
ment of mice by IL­1 injection before sensitization. Al­
though this treatment did not affect the CHS response in WT 
mice, it fully restored it in the P2X7
/ mice (Fig. 7 C).   
Figure 4.  P2X7
/ BMDCs fail to process 
and release mature IL-1. (A) P2X7
/ and 
WT BMDCs were left untreated or were 
treated with 1 µg/ml LPS and/or 5 mM ATP for 
12 h. Western blot analysis was performed to 
detect pro–IL-1 and mature IL-1 in the 
culture supernatant. Supernatant from LPS + 
ATP–stimulated macrophages (MP sup) or 
recombinant pro–IL-1 was used as positive 
control. The data are representative of two 
independent experiments. (B) The same super-
natants were used to detect IL-1 secretion 
by ELISA (***, P < 0.001). (C and D) BMDCs 
were treated with alum at the indicated con-
centrations for 12 h in the presence or ab-
sence of 0.1 µg/ml LPS. IL-1 secretion was 
determined by ELISA. (B–D) Data represent the 
mean of triplicate measurements ± SD and 
are representative for two (B) or three (C and D) 
independent experiments.JEM VOL. 207, November 22, 2010 
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Surprenant and North, 2009), is fur­
ther supported by our in vitro find­
ings. Stimulation of WT BMDCs with 
LPS  and ATP  results  in  production 
and secretion of mature IL­1, whereas 
IL­1 processing and secretion is ab­
rogated in P2X7
/ BMDCs. The fact 
that we can restore this defect with the 
inflammasome activator alum, which 
bypasses P2X7 by direct activation of 
the NLRP3 inflammasome (Eisenbarth 
et al., 2008, Franchi and Núñez, 2008; 
Kool et al., 2008; Li et al., 2008), and the lack of IL­1 release 
from NLRP3/ DCs after stimulation with LPS and ATP 
reveal a functional link between ATP, P2X7, and the NLRP3 
inflammasome in IL­1 processing and secretion in the sen­
sitization  phase  of  CHS.  Similar  results  were  reported  for 
LPS­primed macrophages from P2X7
/ mice, which secrete 
IL­1 when pretreated with the inflammasome activator ni­
gericin (Solle et al., 2001). This is further supported by our 
results demonstrating a failure of TNBS­modified BMDCs 
from ASC/ and NLRP3/ mice (Martinon et al., 2006; 
Sutterwala et al., 2006) to sensitize WT mice. In contrast to 
the results with P2X7 BMDCs, alum pretreatment of these 
DCs fails to restore their sensitizing capacity.
Interestingly, our data support the notion that IL­1 as a 
rapidly induced pathogenic cytokine in the sensitization phase of 
CHS (Enk and Katz, 1992) plays a crucial role. Keratinocytes and 
suggests a P2X7­dependent pathway in the processing and se­
cretion of the key cytokines IL­1 and IL­18 in CHS (Shornick 
et al., 1996; Antonopoulos et al., 2001, 2008; Cumberbatch   
et al., 2001). P2X7­mediated K+ efflux from the cell can activate 
the NLRP3 inflammasome and caspase­1, which is a require­
ment for IL­1 processing and secretion (Solle et al., 2001, 
Mariathasan et al., 2006; Dinarello, 2009). Similar effects are ob­
served upon depletion of intracellular K+ by nigericin and mai­
totoxin (Ferrari et al., 2006; Mariathasan et al., 2006; Di Virgilio, 
2007; Surprenant and North, 2009). Our findings suggest that 
P2X7 is involved in contact allergen–induced and NLRP3   
inflammasome–dependent IL­1 release.
The previously reported link between P2X7 and post­
translational IL­1 processing, which involves the NLRP3 
inflammasome (Ferrari et al., 2006; Mariathasan et al., 2006; 
Di Virgilio, 2007; Idzko et al., 2007; Ghiringhelli et al., 2009; 
Figure 5.  TNCB triggers ATP release in 
the skin. Mice received ATP-dependent  
luciferase-expressing HEK293 cells into the 
right ear pinna. The injected ear was painted 
24 h later with acetone or 3% TNCB in  
acetone, and luciferin was injected i.p.  
immediately after painting. ATP was injected 
into the ear pinna as a positive control.  
Imaging was performed 10 min later. One  
out of three representative experiments is 
shown (top). Bioluminescence was quantified 
for the different conditions (bottom).
Figure 6.  Purinergic receptor antagonism or 
ATP degradation prevents sensitization and 
CHS. (A) The P2X7 receptor antagonist KN-62 was 
injected into the pinna of the left ear of WT mice 
4 h before sensitization. Mice were sensitized 
with 3% TNCB in acetone on the left ear and were 
challenged 5 d later by application of 1% TNCB 
on the right ear. Data represent the mean ear 
swelling of groups of five mice ± SD. (B) Mice 
received apyrase in PBS or PBS as a vehicle con-
trol into the left ear pinna at the time of sensiti-
zation. Mice were sensitized with 3% TNCB or 
acetone as a vehicle control on the left ear for 
sensitization. Challenge was performed with 1% TNCB applied on the right ear 5 d later. The increase of ear thickness was determined 24 h after chal-
lenge. Data represent the mean increase in ear thickness ± SD of groups of five mice. (A and B) One representative of three independent experiments is 
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In the light of recent data showing that ATP can activate 
regulatory T cells and control CHS (Ring et al., 2010), a dual 
role for ATP in inflammation and immunoregulation becomes 
evident. It remains to be determined how the balance between 
proinflammatory and regulatory immune responses is regu­
lated. The kinetics of these responses, the target cells, and the 
purinergic receptors involved may all play a role.
Our study identifies ATP triggering of P2X7 on DCs as a 
crucial step in the induction of skin inflammation by contact 
allergens but not skin irritants such as croton oil. Similar to 
our findings with indirect TLR2 and TLR4 triggering by 
contact allergens such as TNCB, oxazolone, and FITC, via in­
duction of endogenous TLR ligands (Martin et al., 2008), we 
provide evidence that P2X7 activation by contact allergens is 
also indirect. We show that TNCB rapidly induces the release 
of the P2X7 agonist ATP in the skin. We demonstrate that 
TNCB­induced CHS can be readily prevented by injection 
of the P2X7 antagonist KN­62 and the purinergic receptor 
antagonist suramin or by the ATP­degrading enzyme apyrase. 
Further studies will show whether P2X7­specific antagonists 
are also effective in the control of established CHS. In this 
context, our finding that treatment of mice with the IL­1Ra 
Langerhans cells are sources for IL­1 in the skin. A recent   
in  vivo  imaging  study  identified  CD45+CD11b+  myeloid 
leukocytes as primary sources for IL­1 by monitoring mes­
senger RNA induction in vivo (Matsushima et al., 2010).   
In contrast to the failure to sensitize WT mice treated with 
the IL­1Ra anakinra or the absence of CHS in IL­1R/ 
mice, CHS to TNCB was normal in IL­18/ mice. More­
over, pretreatment of P2X7
/ mice with IL­1 fully restored 
CHS. These results show the crucial role of IL­1 in the   
sensitization to TNCB. The extent of IL­1 messenger   
RNA  induction  correlates  with  the  dose  as  well  as  with 
strength of the contact allergen (Lass et al., 2010). Interest­
ingly, it was shown that CHS to DNFB (2,4­dinitrofluoro­
benzene) is also dependent on IL­18 (Klekotka et al., 2010). 
In this study, a role for IL­1R on radiosensitive bone marrow–
derived cells and for IL­18 in radioresistant host­derived   
cells  was  demonstrated  in  bone  marrow  chimeras.  Our 
findings on the role of IL­1 are in line with the study by   
Antonopoulos et al. (2008), who showed that deficient CHS 
in caspase­1/ mice can be restored by pretreatment with 
IL­1 but not with IL­18. The authors concluded that IL­18 
acts upstream of IL­1.
Figure 7.  IL-1R antagonism or deficiency abrogates CHS, whereas IL-1 pretreatment of P2X7
/ mice restores it. (A) Anakinra was injected i.p. 
on days 5, 3, and 1 before sensitization. Sensitization and challenge were performed as in Fig. 1. (B) Mice of the indicated strains were treated with 100 µl 
of 3% TNCB or acetone as vehicle control on day 0. On day 5, all mice received 20 µl of 1% TNCB on the dorsum of the ear pinna as challenge. (A and B) 
One representative of three independent experiments is shown. (C) WT and P2X7
/ mice were injected with IL- in PBS/0.1% BSA or vehicle control 30 min 
before sensitization in the dorsum of the left ear. Mice were sensitized by topical application of 3% TNCB on the dorsum of the right ear on day 0.  
Challenge was performed on day 5 with 1% TNCB on the dorsum of the left ear. One experiment was performed. (A–C) Data represent the mean increase 
in ear thickness ± SD of groups of five mice (**, P < 0.005; ***, P < 0.001).JEM VOL. 207, November 22, 2010 
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The P2X7 receptor antagonist KN­62 (Sigma­Aldrich) was dissolved in 
DMSO at 7.14 mg/ml. Mice were injected with KN­62 diluted in 71.4 µg/ml 
PBS, and 50 µl was injected into the pinna of the left ear 4 h before sensitization 
unless  indicated  otherwise. Apyrase  (2  U  potato  apyrase  grade  7  [Sigma­ 
Aldrich] in 50 µl PBS) was injected into the ear pinna immediately before sen­
sitization unless indicated otherwise. Mice were sensitized with 3% TNCB on 
the same ear and challenged 5 d later on the right ear with 1% TNCB. 24­h 
ear­swelling responses were measured. Anakinra Kineret (Amgen) was injected 
at a dose of 200 µg/mouse i.p. in 200 µl PBS on days 5, 3, and 1 before sensitiza­
tion. The optimal doses and the timing for KN­62 and apyrase treatment were 
determined as shown in Figs. S1 and S3. IL­1 (50 µg in 30 µl PBS/0.1% BSA) 
or PBS/BSA as vehicle control was injected into WT and P2X7
/ mice   
30 min before sensitization in the dorsum of the left ear as described previously 
(Antonopoulos et al., 2008). Mice were sensitized by topical application of 20 µl 
of 3% TNCB on the dorsum of the left ear on day 0. Challenge was performed 
on day 5 with 20 µl of 1% TNCB on the dorsum of the right ear.
Histology of the skin. Ears from vehicle or allergen­sensitized mice were 
removed 24 h after allergen ear challenge and fixed in 3.7% buffered formal­
dehyde. Organ slices of 5 µm were prepared and stained with hematoxylin 
and eosin (H&E).
Induction of irritant contact dermatitis. Mice were painted on both ears 
with 20 µl of 1% croton oil (Sigma­Aldrich) in acetone/olive oil (4:1). The ear 
thickness was measured before and 24 h after application of croton oil.
Alum pretreatment of BMDCs before adoptive transfer. BMDCs were 
harvested on day 7 and modified with TNBS as described previously (Martin 
et al., 2008). For alum stimulation, BMDCs were incubated for 2 h at 37°C in 
RP­10 containing 240 µg/ml aluminum hydroxide (diluted 1:166.7; Imject 
Alum; Thermo Fisher Scientific) unless indicated otherwise. For NLRP3/ 
and ASC/ BMDC transfers into WT mice, 80 µg/ml alum was used to 
avoid stimulation of recipient WT cells caused by alum carryover. Cells were 
washed three times in PBS before adoptive transfer by i.c. injection.
In vivo bioluminescence imaging of ATP release. In vivo biolumines­
cence imaging was performed as previously described (Edinger et al., 2003). 
In brief, 5 × 106 HEK293­pmeLUC cells (Pellegatti et al., 2008) were in­
jected into the ear skin in 50 µl PBS. Mice were treated 24 h after cell transfer 
with the contact allergen TNCB (20 µl of 3% TNCB/acetone), the vehicle 
control acetone, or by injection of 50 µl of 1.25 mM ATP/PBS as a positive 
control, followed by i.p. injection of luciferin. 10 min later, the mice were 
imaged with an exposure time of 5 min with an IVIS 100 charge­coupled 
device imaging system (Xenogen) and Igor Pro Carbon (WaveMetrics).
In vitro stimulation of DCs and IL-1 measurement. Stimulation of 
106 BMDCs was performed in 500 µl RP­10 for 12 h with 1 µg/ml LPS in 
the presence or absence of 5 mM ATP or the corresponding controls. No 
significant differences in the viability of BMDCs from WT and P2X7
/ 
DCs were observed by propidium iodide/annexin­V staining. Supernatants 
were used for Western blotting and ELISA to measure IL­1. ELISA   
(OptEIA; BD) was performed according to the manufacturer’s recommenda­
tions. Peritoneal macrophages were prepared and stimulated with LPS and ATP 
as described previously (Metkar et al., 2008), and the supernatant was used as 
positive control for Western blots. For alum stimulation, BMDCs were incu­
bated for 12 h at 37°C in RP­10 containing graded concentrations of alumi­
num hydroxide in the presence or absence of 0.1 µg LPS.
Statistical analysis. Statistical analysis was conducted using one­way analy­
sis of variance with Tukey’s multiple comparison post test and Prism version 
5.00 (GraphPad Software, Inc.). Data are shown as means ± SD. Differences 
between groups as marked by asterisks were statistically significant at P < 
0.05 (*), P < 0.005 (**), or P < 0.001 (***).
Online supplemental material. Fig. S1 shows the dose titration and time 
kinetics for the P2X7 antagonist KN­62. Fig. S2 shows suppression of the 
anakinra efficiently prevents CHS opens the possibility to test 
its efficiency in patients with ACD.
The fact that TLR2 and TLR4, P2X7, or NLPR3 and 
ASC must be functional on DCs to enable them to sensitize 
mice for CHS and that the lack of function of one of these 
pathways is sufficient to abrogate their sensitization potential 
supports our concept of an essential collaborative action of 
these pathways in CHS (Freudenberg et al., 2009). The essen­
tial role of the DC is explained by its unique function as the 
cell type that migrates from the inflamed skin to the lymph 
nodes, communicates the activation of the innate immune 
system to contact allergen–specific T cells, and directs effector 
T cells to the skin (Dudda and Martin, 2004; Edele et al., 
2007; Sigmundsdottir and Butcher, 2008).
Our study may open new perspectives for the treatment 
of ACD with available antagonists of the P2X7 receptor, as re­
cently reported for allergic airway inflammation (Idzko et al., 
2007). So far, our data suggest that P2X7 antagonists may pre­
vent sensitization to contact allergens. It remains to be studied 
whether P2X7 signaling also plays a role in the elicitation 
phase or in chronic contact dermatitis.
MATERIALS AND METHODS
Mice. C57BL/6 WT, C57BL/6 P2X7
/ (Solle et al., 2001), and ASC/ mice 
(Sutterwala et al., 2006) were bred at the animal facility of the University Medical 
Center Freiburg under specific pathogen­free conditions. P2X7
/ mice were 
purchased from The Jackson Laboratory. NLRP3/ mice (Martinon et al., 
2006) were received from M. Kopf (Swiss Federal Institute of Technology   
Zurich, Zurich, Switzerland) with permission from J. Tschopp (University of 
Lausanne, Lausanne, Switzerland). IL­1R/ (Labow et al., 1997) and IL­18/ 
mice (Wei et al., 1999) on C57BL/6 background were a gift from M. Freuden­
berg (Max­Planck­Institute of Immunobiology, Freiburg, Germany). All of the 
experimental procedures were in accordance with institutional, state, and federal 
guidelines on animal welfare. The animal experiments were approved by the 
Regierungspräsidium Freiburg and supervised by the Animal Protection Repre­
sentatives of the University Medical Center Freiburg.
Chemicals and reagents. TNBS, FITC, oxazolone, and croton oil were 
purchased from Sigma­Aldrich. TNCB was purchased from VeZerf Laborsyn­
thesen GmbH. LPS of Salmonella abortus equi was purchased from Enzo Life 
Sciences, Inc. IL­1 ELISA was purchased from BD (OptEIA ELISA set). 
Recombinant IL­1 was purchased from R&D Systems. Flow cytometry 
was performed as described previously (Martin et al., 2008) on a FACScan 
instrument with CellQuest Pro software (BD).
Generation of BMDCs. BMDCs were prepared as previously described 
(Martin et al., 2008). Overall DC viability was not significantly influenced by 
the lack of P2X7 as controlled by growth rate and cell yield in DC cultures 
from P2X7
/ compared with WT mice.
Immunization and induction of CHS. Mice were sensitized by painting 
the abdominal skin with 100 µl of 3% TNCB/acetone or acetone alone as 
vehicle control on day 0. Epicutaneous application of 20 µl of 1% TNCB on 
the dorsum of both ears on day 5 was used for elicitation. Alternatively, mice 
were sensitized by i.c. injection of 3 × 105 unmodified or TNBS­modified 
BMDCs in 2 × 50 µl PBS into two sites of the shaved abdomen (Martin   
et al., 2008) followed by elicitation on day 5 by painting the dorsum of both 
ears with 1% TNCB. CHS to oxazolone was induced by sensitization with 
150 µl of 3% oxazolone in ethanol, followed by ear challenge with 20 µl of 
1% oxazolone/ethanol 6 d later. Ear measurement was performed before and 
24 h after challenge using an engineer’s thickness gauge (Mitutoyo).2618 P2X7 receptor in contact hypersensitivity | Weber et al.
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